H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Jounce Therapeutics Inc (JNCE) today and set a price target of $13. The company’s shares closed yesterday at $4.83.
Chattopadhyay wrote:
“We re-iterate our $13 12-month target, which is based on a 12-year DCF and limited to the prospects of vopra (JTX-2011), with potential upside from JTX-4014 and JTX-8064. Our DCF is driven by: beta of 1.2 terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.6%, and tax rate of 15% beginning in FY 2026.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 0.8% and a 43.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Autolus Therapeutics Plc.
The word on The Street in general, suggests a Hold analyst consensus rating for Jounce Therapeutics Inc with a $13 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.78 and a one-year low of $2.66. Currently, Jounce Therapeutics Inc has an average volume of 145.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.
